3-rx.comCustomer Support
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics

\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>

Join our Mailing List


You are here : 3-RX.com > Home > Breast Cancer -

Letrozole tops tamoxifen for early breast cancer

Breast CancerDec 29, 05

As add-on therapy for breast cancer, letrozole appears to be more effective than tamoxifen in reducing the risk of the disease recurring, new research suggests.

Dr. Beat Thurlimann, from the Senology Center of Eastern Switzerland in Kantonsspital, and colleagues compared the outcomes of 8010 women who were randomly assigned to one of four treatment regimens for 5 years: letrozole; letrozole followed by tamoxifen; tamoxifen; or tamoxifen followed by letrozole.

In the current analysis of the data, reported in Thursday’s New England Journal of Medicine, the researchers focused on the drugs that the women were treated with initially. Therefore, women who received letrozole initially were compared with those who received tamoxifen initially.

During an average follow-up period of just over 2 years, a total of 351 cancer recurrences were noted in the letrozole group, while 428 occurred in the tamoxifen group. Compared with tamoxifen, letrozole cut the risk of recurrent disease by 19 percent, the report indicates.

Treatment with tamoxifen was associated with higher rates of blood clots, endometrial cancer, and vaginal bleeding. On the other hand, letrozole therapy was tied to higher rates of skeletal and heart problems, as well as high cholesterol levels.

The study was supported by Novartis Pharmaceuticals Corp., which markets letrozole as Femara.

Letrozole is in a class of drugs known as aromatase inhibitors. The new findings “validate the results of previous studies showing that aromatase inhibitors were more efficacious than tamoxifen” in postmenopausal women with early-stage breast cancer, Dr. Sandra M. Swain comments in a related editorial.

Swain, from the National Cancer Institute in Bethesda, Maryland, adds that longer follow-up from several ongoing studies is needed “to enable us to offer patients sound advice regarding the benefits and long-term risks of aromatase inhibitors.”

SOURCE: New England Journal of Medicine, December 28, 2005.

Print Version
comments powered by Disqus

  Fat grafting technique improves results of breast augmentation
  UW research shows sensor technology may help improve accuracy of clinical breast exams
  Generic Breast Cancer Drugs Boost Adherence
  New models of drug-resistant breast cancer point to better treatments
  Breast tomosynthesis increases cancer detection and reduces recall rates
  2 views are better than 1 in 3-D breast screening
  Study reveals genomic similarities between breast cancer and ovarian cancers
  Moderate exercise tied to lower breast cancer risk
  Risk for some cancers rises with U.S. obesity rate
  New genomic test spares patients chemotherapy with no adverse effect on survival
  Breast Cancer In Black Women Is A Different Disease
  Combination of Everolimus and Exemestane Improves Progression-Free Survival for Women with Metastatic Breast Cancer


Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site